- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01958047
A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability
A Phase 1 Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single Dose of ASP3652 in Caucasian, Japanese, Black/African and Chinese Healthy Male and Female Subjects
Study Overview
Status
Intervention / Treatment
Detailed Description
This is an open label study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of a single dose of ASP3652 in healthy male and female subjects from Caucasian, Japanese, Black/African and Chinese origin.
A total of 64 healthy male and female subjects are included in this study (16 subjects per race group). Each race group comprises 8 female subjects and 8 male subjects.
Screening assessments are performed from Day -22 to Day -2, and subjects are admitted to the clinic on Day -1, where they remain until Day 4. On Day 1, the subjects receive a single oral dose of ASP3652, and are discharged on Day 4 when all assessments have been performed and if there are no medical reasons to stay longer. An end of study visit (ESV) is performed 7-14 days after discharge.
For each race group, plasma samples for PK and PD analysis are collected. Vital signs, safety electrocardiogram (ECG) measurements, safety laboratory assessments, physical examination, adverse events (AEs) and concomitant medications are monitored throughout study.
In order to identify potential relationships between dietary intake and the PK of a single dose of ASP3652, all subjects record their diet for 3 days during the screening period in order to assess daily dietary intake (including total daily caloric intake; daily cholesterol intake; and total fat, saturated fat, carbohydrate and protein as a percentage of total calories).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Harrow, United Kingdom, H1 3UJ
- PAREXEL Early Phase Clinical Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject is a healthy male or female subject from Caucasian, Japanese, Black/African or Chinese origin. Both parents and all 4 grandparents should be of the same race.
- Subjects of Japanese or Chinese origin should be born in their respective countries and should not have lived outside of their countries for more than 5 years and 10 years, respectively.
- The subject has a Body Mass Index (BMI) in the range 18.5 - 30.0 kg/m2, inclusive (subject from Caucasian or Black/African origin) or in the range 17.5 - 29.0 kg/m2, inclusive (subject from Japanese or Chinese origin). The subject weighs at least 50 kg (subject from Caucasian or Black/African origin) or at least 45 kg (subject from Japanese or Chinese origin).
Exclusion Criteria:
- Female subject who is pregnant, has been pregnant within 6 months before screening, or breast feeding within 3 months before screening.
- Known or suspected hypersensitivity to ASP3652 or any components of the formulation used.
- The subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to admission to the Clinical Unit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ASP3652
One single dose
|
Oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of ASP3652 in plasma measured by Cmax
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
maximum observed plasma concentration (Cmax)
|
Day 1 to Day 4 (16 blood samples taken)
|
Pharmacokinetics of ASP3652 in plasma measured by AUClast
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)
|
Day 1 to Day 4 (16 blood samples taken)
|
Pharmacokinetics of ASP3652 in plasma measured by AUCinf
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
area under the plasma concentration-time curve from time zero extrapolated to the infinite time (AUCinf)
|
Day 1 to Day 4 (16 blood samples taken)
|
Pharmacokinetics of ASP3652 in plasma measured by tmax
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
time to attain Cmax (tmax)
|
Day 1 to Day 4 (16 blood samples taken)
|
Pharmacokinetics of ASP3652 in plasma measured by tlag
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
PK lag time (tlag)
|
Day 1 to Day 4 (16 blood samples taken)
|
Pharmacokinetics of ASP3652 in plasma measured by t1/2
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
apparent terminal elimination half-life (t1/2)
|
Day 1 to Day 4 (16 blood samples taken)
|
Pharmacokinetics of ASP3652 in plasma measured by Vz/F
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
apparent volume of terminal phase distribution at steady state (Vz/F)
|
Day 1 to Day 4 (16 blood samples taken)
|
Pharmacokinetics of ASP3652 in plasma measured by CL/F
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
apparent clearance after oral administration at steady state (CL/F)
|
Day 1 to Day 4 (16 blood samples taken)
|
Pharmacokinetics of ASP3652 in plasma measured by Vz/F/kg
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
body weight-adjusted apparent volume of terminal phase distribution at steady state (Vz/F/kg)
|
Day 1 to Day 4 (16 blood samples taken)
|
Pharmacokinetics of ASP3652 in plasma measured by CL/F/kg
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
body weight-adjusted apparent clearance after oral administration at steady state (CL/F/kg)
|
Day 1 to Day 4 (16 blood samples taken)
|
Pharmacokinetics of ASP3652 metabolites in plasma measured by Cmax
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
Day 1 to Day 4 (16 blood samples taken)
|
|
Pharmacokinetics of ASP3652 metabolites in plasma measured by AUClast
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
Day 1 to Day 4 (16 blood samples taken)
|
|
Pharmacokinetics of ASP3652 metabolites in plasma measured by AUCinf
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
Day 1 to Day 4 (16 blood samples taken)
|
|
Pharmacokinetics of ASP3652 metabolites in plasma measured by tmax
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
Day 1 to Day 4 (16 blood samples taken)
|
|
Pharmacokinetics of ASP3652 metabolites in plasma measured by tlag
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
tlag
|
Day 1 to Day 4 (16 blood samples taken)
|
Pharmacokinetics of ASP3652 metabolites in plasma measured by t1/2
Time Frame: Day 1 to Day 4 (16 blood samples taken)
|
Day 1 to Day 4 (16 blood samples taken)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma levels of arachidonoyl-ethanolamide (AEA, or anandamide), oleoyl-ethanolamide (OEA) and palmitoyl-ethanolamide (PEA) after a single dose of ASP3652
Time Frame: Day 1 to Day 4 (12 blood samples taken)
|
maximum response (Rmax), time of the maximum response (tmax R), area under the response curve (AUR)
|
Day 1 to Day 4 (12 blood samples taken)
|
Safety and tolerability of a single dose of ASP3652
Time Frame: Screening to ESV (at least 39 safety assessments)
|
vital signs, safety electrocardiogram measurements, safety laboratory assessments, physical examination and adverse events (AEs)
|
Screening to ESV (at least 39 safety assessments)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 3652-CL-0054
- 2012-001476-11 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Shouyao Holdings (Beijing) Co. LTDNot yet recruiting
-
Abbisko Therapeutics Co, LtdNot yet recruiting
-
Vigonvita Life SciencesRecruiting
Clinical Trials on ASP3652
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics of ASP3652United Kingdom
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics of ASP3652 | Pharmacodynamics of ASP3652United Kingdom
-
Astellas Pharma IncCompletedChronic Pelvic Pain Syndrome | Chronic Abacterial ProstatitisCzech Republic, Germany, Latvia, Lithuania, Poland, Spain
-
Astellas Pharma Europe B.V.CompletedPain | Urologic Diseases | Cystitis, Interstitial | Urinary Bladder DiseaseBelgium, Czechia, Denmark, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russian Federation, Spain
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics of ASP3652 | Pharmacodynamics of ASP3652Netherlands
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics | Pharmacodynamics | SafetyNetherlands
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Drug-Drug Interaction (DDI)United Kingdom